Bausch Health's CABTREO Receives Positive Reimbursement Endorsements in Canada

Bausch Health Companies Inc. announced the approval of PrCABTREOTM, a new triple-combination treatment for acne vulgaris, through positive reimbursement recommendations from Canada's Drug Agency and Quebec's INESSS. CABTREO, targeting patients aged 12 and older, combines clindamycin phosphate, adapalene, and benzoyl peroxide. These endorsements mark a step towards public drug plan reimbursement in Canada.

CABTREO stands out as the only Health Canada-approved triple-component topical treatment for acne. It combines an antibiotic, a retinoid, and an antibacterial agent, aiming for safe and effective results. Clinical trials reported a 50% treatment success rate, and 70% reduction in lesion counts.

Available in Canadian pharmacies, CABTREO offers a new option for acne treatment, with notable support from dermatology stakeholders. However, it carries specific usage warnings and should be applied cautiously near hair and colored fabrics.